- The cited “Blum Capital losing streak” claim could not be verified from available reporting and appears to be a misattribution versus public disclosures for Blum Holdings (BLMH).
- BLMH shows operational improvement, with strong 2024 results and higher 2025 revenue and gross margins, but profitability remains inconsistent.
- Liquidity is precarious, with cash near $0.37M, a ~$20.8M working-capital deficit, and disclosed material internal-control weaknesses.
- Debt conversions and new secured borrowing aim to stabilize the balance sheet, but add dilution and complexity while acquisitions increase execution and funding risk.
Read More
The query “Blum Capital on Losing Streak” appears to misattribute challenges to the private equity firm Blum Capital; searches did not surface authoritative content linking that firm to current investment underperformance. Instead, detailed financial disclosures are available for Blum Holdings, Inc. (BLMH), whose results show a company in the midst of a restructuring and turnaround phase.
BLMH’s fiscal year 2024 marked a dramatic shift: net income of $33.1 million (versus losses of $14.1 million in 2023 and $188.7 million in 2022), revenue growth of 67%, and a 62% reduction in liabilities. But adjusted EBITDA from continuing operations remained negative (~$10.9 million) reflecting recognition of underlying operations lagging structural profitability. In Q1–Q2 2025, revenue increased ≈26–59% YoY in different periods; gross margin improved to ~49–53%. However, net loss deepened in Q2 to $1.9 million due to margin dilution and integration costs.
Liquidity is a major concern. As of June 30, 2025, cash and cash equivalents stood at approximately $0.37 million with working capital deficit sharply widening (to ~$20.8 million). Management’s disclosures of material weaknesses in internal controls raise additional risks of misstatement or governance deficiencies.
To address debt and simplify structure, Blum converted $3.05 million of unsecured debt into equity at $0.98 per share and issued a $525,000 secured promissory note with an 8% interest rate maturing Dec 2027. This reduces unsecured liabilities but adds fixed debt service obligations and dilutes existing equity. Strategic acquisitions (e.g., in Northern California, LOI for a Bay Area dispensary expected to generate over $12 million) indicate an intent to scale, but also imply risk in execution and further capital requirements.
Strategic implications for investors, creditors, or potential acquirers include balancing operational improvement with financial distress. While execution has been strong in reduction of legacy burdens and restructuring, the company’s financial foundations are still fragile. The risk/reward profile remains asymmetric—substantial upside if federal tax reform (especially 280E or re-scheduling) occurs, but severe downside if cash flow or capital markets fail to provide the needed support, or further legal/regulatory issues arise.
Open questions include: What is the timeline for achieving positive operating cash flow? Can the company raise non-dilutive capital at favorable terms? How likely is federal tax reform or regulatory relief (e.g., 280E)? What contingency plans exist for adverse margin pressures or revenue shortfalls? And how trustworthy are the financial reports given admitted internal control issues?
Supporting Notes
- BLMH reported net income of $33.1 million for fiscal 2024, up from losses of $14.1 million in 2023 and $188.7 million in 2022.
- Revenue in 2024 rose 67% YoY to $13.0 million; liabilities dropped by 62% to $29.6 million.
- In Q1 2025, revenue rose 26% YoY to $2.24 million; gross margin hit 53%; operating expenses dropped to $2.5 million from $4.4 million YoY.
- In Q2 2025, revenue increased to $3.5 million (from $2.24M in Q1 2025); operating expenses were flat vs Q1; net loss widened to $1.9 million from $0.6 million.
- As of June 30, 2025: cash and cash equivalents ~$0.37 million; working capital deficit ~$20.8 million; current assets just 8% of current liabilities.
- The unsecured debt conversion ($3.05 million to equity) and issuance of secured promissory note (8% interest, maturity Dec 31, 2027) designed to reduce liability burden but introduce fixed obligations and dilution.
- Management disclosed material weaknesses in internal control over financial reporting as of June 30, 2025.
- While EBITDA turned positive (~$57,000) in Q1 2025, adjusted EBITDA from continuing operations still negative (~$0.4M loss), showing progress but not full profitability.
- The LOI to acquire a licensed retail cannabis operator in Northern California is expected to generate over $12 million in revenue, more than doubling the company’s annual revenue if closed under revised terms: $1.3 million cash, secured note, etc.